← Volver a la portada
Estados Unidos · Revistas de economía · Markets Insider (Business Insider)

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Publicado por Markets Insider (Business Insider) · Estados Unidos hace 1 h
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Markets Insider (Business Insider)

Resumen detallado

MALVERN, Pa., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health and provider of NeuroStar® TMS technology and direct…

MALVERN, Pa., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health and provider of NeuroStar® TMS technology and direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced the granting of inducement award(s) to one non-executive employee as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), this award was approved by Neuronetics’ Compensation Committee and made as a material inducement to their respective employment with the Company.

About Neuronetics Neuronetics, Inc. is a leader in interventional mental health, combining innovative treatment technologies with direct patient care. Through its NeuroStar® Advanced Therapy system, the company is a leading provider of transcranial magnetic stimulation (TMS) treatment and, through Greenbrook, operates one of the largest interventional psychiatry clinic networks in the United States, offering both TMS and SPRAVATO® therapies. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped.

The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com.

Neuronetics Contact:Investors:Mark Klausner or Aman Patel ICR Healthcare443-213-0499ir@neuronetics.com

References 1 The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated.

Inicio del artículo, extracto de Markets Insider (Business Insider). Para leer el resto, abra el artículo en el sitio del medio.

Leer el artículo completo en Markets Insider (Business Insider) Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (markets.businessinsider.com)

También te puede interesar